Polymerized fibrin

Polymerized fibrin is the insoluble protein matrix that forms the structural backbone of blood clots. It is produced when the enzyme thrombin cleaves fibrinopeptides from the soluble precursor fibrinogen, allowing the resulting fibrin monomers to spontaneously polymerize into long protofibrils and fibers (StatPearls, 2023). This meshwork is subsequently stabilized by Factor XIIIa, which introduces covalent cross-links between fibrin chains to provide mechanical stability and resistance to premature degradation (PubMed, PMID: 30135610). While essential for physiological hemostasis and wound repair, the pathological accumulation of polymerized fibrin is the hallmark of obstructive thrombi in conditions such as myocardial infarction, ischemic stroke, and deep vein thrombosis (American Heart Association, 2024). In clinical medicine, polymerized fibrin is the primary target for thrombolytic agents like alteplase and tenecteplase, which promote the conversion of plasminogen to plasmin, the enzyme responsible for fibrinolysis (FDA, 2023). Additionally, because it is absent from the circulating blood and specific to clots, polymerized fibrin serves as a high-affinity target for molecular imaging probes and targeted drug delivery systems (Journal of Thrombosis and Haemostasis, 2021). The degradation of this polymer releases specific fragments, such as D-dimer, which are used clinically as biomarkers for thrombotic activity (Mayo Clinic, 2023). Therapeutic manipulation of fibrin must balance the need to dissolve dangerous clots with the risk of impairing normal hemostasis, which can lead to severe bleeding complications.

Other names

FibrinFibrin polymerInsoluble fibrinFibrin clotCross-linked fibrin

Fibrinolysis via plasminogen activation; direct enzymatic degradation of the fibrin meshwork; fibrin-specific binding for diagnostic imaging.